{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"64.11","value":"30.1"},{"groupId":"OG001","spread":"41.10","value":"39.4"}]}],"title":"24-hours post-dose [N=48, 36]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.11","value":"10.4"},{"groupId":"OG001","spread":"15.80","value":"12.6"}]}],"title":"72-hours post-dose [N=56, 38]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.97","value":"2.8"},{"groupId":"OG001","spread":"5.00","value":"3.5"}]}],"title":"7 days post-dose [N=55, 40]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.30","value":"1.6"},{"groupId":"OG001","spread":"3.54","value":"2.2"}]}],"title":"4 weeks post-dose [N=46, 37]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.41","value":"2.1"},{"groupId":"OG001","spread":"4.62","value":"2.4"}]}],"title":"8 weeks post-dose [N=37, 35]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.79","value":"1.3"},{"groupId":"OG001","spread":"4.90","value":"2.9"}]}],"title":"12 weeks post-dose [N=38, 31]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"description":"High sensitivity C-reactive protein (hsCRP) levels in blood serum were measured by a central laboratory in order to identify the presence of inflammation, to determine its severity, and to monitor the response to treatment.\n\nData are reported for the last post-baseline flare for participants who were randomized to and re-treated with canakinumab, and for the first post-baseline flare treated with canakinumab for participants randomized to triamcinolone acetonide and who were switched to canakinumab in extension study 2.","dispersionType":"Standard Deviation","groups":[{"description":"Participants who received canakinumab 150 mg in the Ccre study and who were re-treated with canakinumab 150 mg for new flares during the overall 72 weeks. Data are reported for the last post-baseline flare for participants in this arm.","id":"OG000","title":"Re-treated With Canakinumab 150 mg"},{"description":"Participants who received triamcinolone acetonide (triam) 40 mg in the core study and who were switched to canakinumab 150 mg for treatment of new flares in extension study 2. Data are reported for the first post-baseline flare treated with canakinumab.","id":"OG001","title":"Triam Switched to Canakinumab"}],"paramType":"MEAN","populationDescription":"Modified Analysis Set (MAS) consisting of all FAS patients who were either re-treated or switched to canakinumab during the 72 weeks. At each timepoint only patients with a value at both baseline flare and the new flare are included.","reportingStatus":"POSTED","timeFrame":"24 hours, 72 hours, 7 days, 4, 8 and 12 weeks post-dose for the last post-baseline flare for the canakinumab re-treated arm and for the first post-baseline flare treated with canakinumab in the triamcinolone acetonide arm during the overall 72 weeks.","title":"High-sensitivity C-reactive Protein (hsCRP) Levels for Participants Re-treated With or Switched to Canakinumab","type":"SECONDARY","unitOfMeasure":"mg/L"}